Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 19, Issue 1, Pages 99-142Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2014.879291
Keywords
binge eating; medication; obesity; pharmacotherapy; placebo
Categories
Funding
- National Institute of Health [R01 DK49587, R01 DK073542, K24 DK070052]
Ask authors/readers for more resources
Introduction: This study evaluated controlled treatment studies of pharmacotherapy for binge eating disorder (BED). Areas covered: The primary focus of the review was on Phase II and III controlled trials testing medications for BED. A total of 46 studies were considered and 26 were reviewed in detail. BED outcomes included binge eating remission, binge eating frequency, associated eating disorder psychopathology, associated depression and weight loss. Expert opinion: Data from controlled trials suggest that certain medications are superior to placebo for stopping binge eating and for producing faster reductions in binge eating, and - to varying degrees - for reducing associated eating disorder psychopathology, depression and weight loss over the short term. Almost no data exist regarding longer-term effects of medication for BED. Except for topiramate, which reduces both binge eating and weight, weight loss is minimal with medications tested for BED. Psychological interventions and the combination of medication with psychological interventions produce binge eating outcomes that are superior to medication-only approaches. Combining medications with psychological interventions does not significantly enhance binge eating outcomes, although the addition of certain medications enhances weight losses achieved with cognitive-behavioral therapy and behavioral weight loss, albeit modestly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available